New combo pill aims to boost cystic fibrosis treatment

NCT ID NCT07108153

Ongoing Disease control Sponsor: Sionna Therapeutics Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests whether adding a new drug called SION-719 to the standard CF medication Trikafta is safe and helps people with cystic fibrosis who have two copies of the F508del mutation. Sixteen participants will receive either SION-719 or a placebo alongside their usual Trikafta. The main focus is on safety, but researchers will also measure changes in sweat chloride, a key marker of CFTR function.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: SION-719 (added to Trikafta)
What this could lead to: If successful, this could point toward a more effective treatment for cystic fibrosis by improving lung function and reducing symptoms when combined with existing therapy.
What could go wrong: This is a small, early-phase study with only 16 participants, so results may not apply to everyone. The main goal is safety, and it's unclear if the added drug will provide meaningful benefit.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for CYSTIC FIBROSIS (CF) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cystic fibrosis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

CYSTIC FIBROSIS (CF)

Contacts and locations

Locations

Boston Children's Hospital

Boston, Massachusetts, 02115, United States
Columbia University

New York, New York, 10032, United States
Gold Coast University Hospital

Southport, Queensland, 4215, Australia
Johns Hopkins

Baltimore, Maryland, 21205, United States
Medical University of South Carolina

Charleston, South Carolina, 29425, United States
Monash University

Melbourne, Victoria, 3004, Australia
National Jewish Health

Denver, Colorado, 80206, United States
New York Medical College

Hawthorne, New York, 10532, United States
Royal Prince Alfred Hospital

Camperdown, New South Wales, 2050, Australia
University Hospital of Cleveland

Cleveland, Ohio, 44106, United States
University of Iowa

Iowa City, Iowa, 52242, United States
University of Washington

Seattle, Washington, 98195, United States
Washington University

St Louis, Missouri, 63110, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.